News Servier and Oncodesign announce Parkinson's R&D tie-up Servier and Oncodesign have announced a strategic partnership for R&D into potential drug candidates for Parkinson’s disease.
News Servier expands global footprint post Shire deal Following its acquisition of Shire’s oncology business in April, Servier is taking steps to expand its presence in the US and China.
News Shire's $2.4bn oncology sell-off seen as Takeda spoiler Move seen as attempt to fend off Takeda takeover
News Safety restrictions spell the end for Servier osteoporosis d... Sales of Protelos hit by safety restrictions.
News Servier and Pfizer begin trials for off-the-shelf T-cell can... Companies hope to challenge traiblazers Novartis and Kite.
News After taking lead in CAR-T, Cellectis drug snapped up by Pfi... Pfizer and Servier have snapped up the rights to UCART19, after the immunotherapy treatment showed hugely encouraging results in a single patient.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.